Objective: To systematically review the efficacy and safety of sacubitril-valsartan in the
treatment of acute myocardial infarction complicated with heart failure and to observe …

Aims We aimed to investigate whether sacubitril–valsartan could further improve the
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …

Background Sacubitril–valsartan has been widely reported for reducing the risk of
cardiovascular death and improving left ventricular remodeling in patients with heart failure …

Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by
comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor …

Patients who develop heart failure (HF) after an acute myocardial infarction (AMI) are at
higher risk of adverse fatal and nonfatal outcomes. Studies have shown sacubitril/valsartan …

Background: infarction (AMI) can be reduced by the use of sacubitril/valsartan. However, the
therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent. In this paper …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Abstract Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death
or heart failure hospitalization and improve symptoms in chronic heart failure with reduced …

Aims This study sought to assess the effect of treatment of sacubitril/valsartan (S/V) on
improving cardiac function and reversing cardiac remodelling in patients with acute coronary …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …